Limits...
Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Liao KL, Bai XF, Friedman A - PLoS ONE (2014)

Bottom Line: In the present paper we develop a mathematical model based on these experimental results.We include in the model an anti-IL-35 drug as treatment.We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing.

View Article: PubMed Central - PubMed

Affiliation: Mathematical Biosciences Institute, The Ohio State University, Columbus, Ohio, United States of America.

ABSTRACT
Interleukin-35 (IL-35), a cytokine from the Interleukin-12 cytokine family, has been considered as an anti-inflammatory cytokine which promotes tumor progression and tumor immune evasion. It has also been demonstrated that IL-35 is secreted by regulatory T cells. Recent mouse experiments have shown that IL-35 produced by cancer cells promotes tumor growth via enhancing myeloid cell accumulation and angiogenesis, and reducing the infiltration of activated CD8[Formula: see text] T cells into tumor microenvironment. In the present paper we develop a mathematical model based on these experimental results. We include in the model an anti-IL-35 drug as treatment. The extended model (with drug) is used to design protocols of anti-IL-35 injections for treatment of cancer. We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing. We also find that the percentage of tumor reduction under anti-IL-35 treatment improves when the production of IL-35 by cancer is increased.

Show MeSH

Related in: MedlinePlus

Comparison of continuous versus intermittent treatment in different production rate  with drug strength .(A), (B), and (C) are the profiles of total numbers of , under , and , respectively. The solid curve is for case (i) that no dosing of anti-IL-35 in tumor cells. The dashed and dotted curves are for tumor cells with continuous (case (ii)) and intermittent (case (iii)) drug injections, respectively. The dashed-dot curve  is the case that there is no IL-35 in the tumor microenvironment, i.e.,  and , for .
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214702&req=5

pone-0110126-g004: Comparison of continuous versus intermittent treatment in different production rate with drug strength .(A), (B), and (C) are the profiles of total numbers of , under , and , respectively. The solid curve is for case (i) that no dosing of anti-IL-35 in tumor cells. The dashed and dotted curves are for tumor cells with continuous (case (ii)) and intermittent (case (iii)) drug injections, respectively. The dashed-dot curve is the case that there is no IL-35 in the tumor microenvironment, i.e., and , for .

Mentions: We use matlab with and in dimensional variables. Figure 4 shows that the temporal growth of the total numbers of tumor cells, as functions of time, under


Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Liao KL, Bai XF, Friedman A - PLoS ONE (2014)

Comparison of continuous versus intermittent treatment in different production rate  with drug strength .(A), (B), and (C) are the profiles of total numbers of , under , and , respectively. The solid curve is for case (i) that no dosing of anti-IL-35 in tumor cells. The dashed and dotted curves are for tumor cells with continuous (case (ii)) and intermittent (case (iii)) drug injections, respectively. The dashed-dot curve  is the case that there is no IL-35 in the tumor microenvironment, i.e.,  and , for .
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214702&req=5

pone-0110126-g004: Comparison of continuous versus intermittent treatment in different production rate with drug strength .(A), (B), and (C) are the profiles of total numbers of , under , and , respectively. The solid curve is for case (i) that no dosing of anti-IL-35 in tumor cells. The dashed and dotted curves are for tumor cells with continuous (case (ii)) and intermittent (case (iii)) drug injections, respectively. The dashed-dot curve is the case that there is no IL-35 in the tumor microenvironment, i.e., and , for .
Mentions: We use matlab with and in dimensional variables. Figure 4 shows that the temporal growth of the total numbers of tumor cells, as functions of time, under

Bottom Line: In the present paper we develop a mathematical model based on these experimental results.We include in the model an anti-IL-35 drug as treatment.We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing.

View Article: PubMed Central - PubMed

Affiliation: Mathematical Biosciences Institute, The Ohio State University, Columbus, Ohio, United States of America.

ABSTRACT
Interleukin-35 (IL-35), a cytokine from the Interleukin-12 cytokine family, has been considered as an anti-inflammatory cytokine which promotes tumor progression and tumor immune evasion. It has also been demonstrated that IL-35 is secreted by regulatory T cells. Recent mouse experiments have shown that IL-35 produced by cancer cells promotes tumor growth via enhancing myeloid cell accumulation and angiogenesis, and reducing the infiltration of activated CD8[Formula: see text] T cells into tumor microenvironment. In the present paper we develop a mathematical model based on these experimental results. We include in the model an anti-IL-35 drug as treatment. The extended model (with drug) is used to design protocols of anti-IL-35 injections for treatment of cancer. We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing. We also find that the percentage of tumor reduction under anti-IL-35 treatment improves when the production of IL-35 by cancer is increased.

Show MeSH
Related in: MedlinePlus